Abstract: The invention relates to method of treating chronic inflammatory diseases in subjects in need thereof by administering calcium lactate as an active agent. The calcium lactate can be provided in a pharmaceutical, food, or nutrient composition.

Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

Abstract: A composition and method for treating lice and removing nits from human hair, the composition including an alcohol; an inorganic salt in an amount less than 10 wt %; one or more essential oils and/or plant essences; and purified water. The composition may optionally include a surfactant to reduce separation of the ingredients of the composition and increase the appearance of homogeneity within the composition. The method may include applying the composition to human hair and the scalp and combing the hair to remove the lice and nits.

Abstract: Provided herein are formulations containing copper ions and methods of treating underlying infections and conditions caused by coronavirus, particularly COVID-19, and influenzas, particularly influenza A and/or influenza B using such formulations. Methods of treating the underlying viruses and their resultant conditions using topical copper ion treatments are provided. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension may be combined with various carriers to form the copper ion treatment including creams or solutions. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

Abstract: Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis.

Abstract: A disinfectant composition useful in shrimp aquaculture and a process for using such a disinfectant, in which there is a composition containing a) 25 to 87 wt. % of KHSO5 containing triple salt b) 1 to 20 wt. % of at least one H2N(CH2)nSO3H compound with n being 0, 1, 2 or 3, c) 1 to 8 wt. % of a surfactant d) 1 to 60 wt. % of a C2-C10 aliphatic dicarboxylic acid, optionally substituted with a hydroxyl and/or carboxylic group and e) 10 to 30 wt. % alkali metal phosphate.

Abstract: A hydrating cosmetic composition for keratinous substrates that includes a stabilized anhydrous balm that includes at least one glycol humectant dispersed in a stabilized anhydrous fatty phase that includes at least one plant derived butter, a blend of structuring waxes, and a blend of fatty compounds and a surfactant.

Abstract: The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.

Abstract: The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a Factor IX (FIX) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a FIX polypeptide. The present invention is directed to a pre-lyophilization formulation comprising: (a) a Factor IX (FIX) polypeptide having FIX coagulation activity; (b) a buffering agent; (c) a stabilizing agent; (d) a bulking agent; and (e) a surfactant, wherein the formulation has a fill volume of less than about 5 mL, and wherein each of (a)-(e) are at an amount per vial (mg/vial) sufficient to allow (1) improved stability of the FIX polypeptide when lyophilized.

Abstract: The invention discloses sedoheptulose for use in the prevention or treatment of inflammation.

Abstract: The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP.

Abstract: Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.

Abstract: The present invention provides regenerative formulations, such as regenerative creams and regenerative oils, methods for the manufacture of the regenerative formulations, and methods for using the regenerative formulations. The regenerative formulations comprise essential oils, moisturizers, stabilizers, preservatives, lubricants, and solvents, and can be used to restore hair.

Abstract: The invention discloses the use of sedoheptulose as a nutritional supplement.

Abstract: Disclosed are intravenous hypertonic electrolyte solutions for treating intracranial hypertension while reducing the risk of inducing hyperchloremic metabolic acidosis. The solutions are characterized by a ratio of sodium-to-chloride (Na:Cl) ions of 1.2-1.6 and a total osmolarity of 310-400 mEq/L for a maintenance solution, and a total osmolarity greater than 1000 mEq/L for an initiation solution.

Abstract: A skin external composition comprising a combination of salt and sugar as an active ingredient in an amount effective to treat and prevent vaginosis, together with a pharmaceutically acceptable carrier, and the use thereof.

Abstract: A skin external composition comprising a combination of salt and sugar as an active ingredient in an amount effective to treat and prevent vaginosis, together with a pharmaceutically acceptable carrier, and the use thereof.

Abstract: A mineral mixture including at least' MgO and its equilibrium of Mg(OH)2, and MgCl2, in which MgO—Mg(OH)2 constitutes between 85 and 99.99% by weight; and MgCl2 constitutes between 0.01 and 15% by weight of the magnesium compounds in the mineral mixture. Preparations containing the salt mixture and the use of the mineral mixture for the production of a pharmaceutical preparation for the prevention or therapy of a condition, the condition being undesired eczema or psoriasis, are also described.

Abstract: The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented.

Abstract: This invention provides concentrated aqueous biocidal solutions formed from bromine chloride, sodium hydroxide, and sulfamic acid. The weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used, the biocidal solution containing at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of the solution.

Abstract: The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20%-37.5% (w/w) leucine, about 58.6-about 75% (w/w) calcium lactate, and about 3.9-about 5% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders.

Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.

Abstract: Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.

Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).

Abstract: Effervescent tablets, powders and granules are provided which may be dissolved in water to produce an effervescent rehydrating beverage. The effervescent tablet, powder and granule compositions of the invention deliver electrolytes and carbohydrates at levels that provide hypotonic, isotonic or slightly hypertonic solution when dissolved in water, with acceptable taste.

Abstract: To provide acidic electrolyzed water, a method for manufacturing acidic electrolyzed water, and a cleanser and a disinfectant containing acidic electrolyzed water which has disinfecting power for a long period of time, and which reduces the burden on living tissue. The acidic electrolyzed water has an effective chlorine concentration of 15 ppm or more, osmotic pressure from 235 mOsm to 435 mOsm, and a chlorine-based electrolyte content of 0.1 mass % or less in terms of sodium chloride.

Abstract: The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20%-37.5% (w/w) leucine, about 58.6-about 75% (w/w) calcium lactate, and about 3.9-about 5% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders.

Abstract: A skin treatment method which includes ionizing oxygen and then mixing the ionized oxygen with saline solution to produce an energized saline solution is disclosed. The method further includes applying the energized saline solution to the skin as a mist-like spray to treat the skin. The system used to carry out the method includes an oxygen concentrator for generating oxygen and an ionizer for imparting an electric charge to the oxygen to produce ionized oxygen. The system also includes a bag of saline solution as well as a peristaltic pump for pumping the saline solution from the bag to a spray nozzle mounted in a handheld wand. The concentrator further includes apparatus for pumping or delivering the oxygen and ultimately the ionized oxygen to the spray nozzle. The spray nozzle mixes and atomizes the ionized oxygen and saline solution to produce a spray-like mist of the same which is then applied to an individual's skin.

Abstract: A skin external composition comprising a combination of salt and sugar as an active ingredient in an amount effective to treat and prevent vaginosis, together with a pharmaceutically acceptable carrier, and the use thereof.

Abstract: The optimum concentration of salt in solutions to combat congestion of the mucosa is a relatively narrow range. This use of in hypertonic saline solutions for treatment of congestion of the mucosa having a concentration within the range of 2.3% to and including 2.7% w/v sodium chloride/water with the most preferred concentration being 2.4% to and including 2.6% w/v of sodium chloride in water brings maximum relief of congestion and for cleansing membranes without causing irritation or discomfort.

Abstract: A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions.

Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.

Abstract: The invention relates to a unique formulated pharmaceutical composition and a novel treatment method of intratumoral injection. The pharmaceutical composition of the invention is the saturated ionic solution of sodium ions and calcium ions (the “medicinal ion bomb”). The invention of intratumoral injection with the “medicinal ion bomb” can be used as the first-line treatment in treating cancer and tumor in nine human organs (carcinoma and tumor of the skin and subcutaneous tissue, breast, prostate, thyroid, lung, liver, genital organ, brain and pancreas) and certain other benign diseases (skin and subcutaneous neoplasm, breast fibrocystic change, benign prostatic hyperplasia and thyroid nodules).

Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.

Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.

Abstract: A composition is described that includes: (a) at least one alkali metal hydrogen sulfate anhydrous, such as sodium hydrogen sulfate anhydrous; (b) at least one salt, that is different than the alkali metal hydrogen sulfate anhydrous, which is selected from alkali metal salt and/or alkaline earth metal salt, such as sodium chloride and/or magnesium sulfate; and (c) optionally a colorant, in which the composition is in the form of a tablet. There is also described a method of forming a treated aqueous stream using the tablet composition. There is further described a method of forming a treated sanitizing aqueous stream that involves combining the treated aqueous stream with a feed sanitizing aqueous stream. In addition, there is described a method of sanitizing a surface that involves applying the treated sanitizing aqueous stream to a surface to be treated, such as animal carcass surfaces.

Abstract: A method of modifying the content of certain bacteria in uncured tobacco material is provided, the method including contacting an uncured tobacco material with a treatment solution, wherein the treatment solution is selected from the group consisting of: (i) a solution comprising salt, sugar, or a combination thereof; (ii) a solution comprising one or more enzymes; and (iii) a solution comprising one or more probiotics, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest. In certain embodiments, the treated tobacco material is subsequently cured, and can optionally be fermented. Smoking articles and smokeless tobacco products including such treated tobacco materials are also provided.

Abstract: A method for preparing the human bowel to undergo colonoscopy. A salt solution, preferable having a 0.9% w/v concentration of sodium chloride in water and warmed to 40 C degrees, is utilized. A series of twisting and maneuvering exercises, such as those used in Yoga, is also performed. A predetermine quantity of the salt solution is consumed during predetermined intervals between the exercise steps, intending to clear and cleanse the colon so as to prepare it to undergo colonoscopy within about 3 to 24 hours after the completion of the preparation.

Abstract: An anhydrous composition is provided. The anhydrous composition may be a tablet configured to dissolve in water, the tablet including Vitamin C (as ascorbic acid), Vitamin E (as dl-alpha-tocopheryl acetate), Magnesium (as magnesium sulfate and magnesium oxide), Zinc (as zinc sulfate), Chloride (as sodium chloride), Sodium (as sodium chloride, sodium bicarbonate and Sodium carbonate), Potassium (as potassium bicarbonate), Salt (as sodium chloride), Aloe Vera, Chamomile (as matricaria recutita), Honey, and/or Stevia Leaf extract. The anhydrous composition may further comprise Citric Acid, Sorbitol, Natural flavor, Wheat Germ Oil, and/or Magnesium Oxide.

Abstract: Compositions, formulations and methods bio-balance the pH of sterile, sodium chloride inhalation and pulmonary irrigation solutions, such that the solutions are bio-similar to the homeostatic pH state of the Human Airway Surface Liquid (ASL) at about 7.4. These solutions are sterile, non-pyrogenic, additive and preservative free, and provided in sterile unit-of-use, blow-fill-seal vials. These solutions are intended for use in the induction of sputum production where sputum production is indicated, such as with Cystic Fibrosis patients and Bronchoalveolar lavage procedures. The solutions can be provided in concentrations from about 0.045% to about 10% sodium chloride in USP/Sterile water. The sodium chloride solutions are homogenous mixtures that include sterile water, sodium chloride, and sodium bicarbonate as a buffer. The solutions are provided in saline concentrations from 0.45% to 10%, for example, concentrations of 0.9%, 3%, 3.5%, 6%, and 7% with a pH of 7.4.

Abstract: The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

Abstract: Effective devices and methods using a chemical denervation agent are provided for treating chronic back pain. The devices and methods comprise a chemical denervation agent to degrade or to shrink at least a portion of a nerve associated with back pain e.g. basivertebral nerve of the lumbar. In some embodiments, the methods and devices are configured to immediately release an effective amount of the chemical denervation agent within 24 hours and provide sustained release of the chemical denervation agent or other therapeutic agent over a period of up to one year to treat chronic back pain.

Abstract: The present invention relates to compositions comprising a plant material and methods for using the same. The methods include extracting or removing a substance from a substrate, or remediating a substrate from a substance. The substance can comprise a hydrocarbon-containing substance, a protein, lipid, wax, fatty acid or fatty alcohol, grease, fat, oil or a combination thereof.

Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: A therapeutic rinse for treating a sore throat. The therapeutic rinse may be stored in a self-heating container that is capable of reaching a temperature of at least 130 degrees Fahrenheit when activated. The therapeutic rinse includes a liquid composition having sodium chloride, water, and a variety of vitamins, minerals and herbs stored in the reservoir of the self-heating container. An antibiotic may also be included in the therapeutic rinse. Before use, the therapeutic rinse may be heated.

Abstract: An array of pharmaceutical formulations characterized by the presence of molecular oxygen comprising four elements which, in combination, furnish benefits for the health of patients with HIV AIDS: (i) weight increase of the patient; (ii) increase of appetite; (iii) reduction of diarrhea; (iv) reduction of the wasting syndrome; (v) increase of stability of mood; (vi) increase of muscular mass. (vii) decrease of opportunistic diseases, in particular infections caused by Candida, herpes virus, cytomegalovirus, Kaposi's sarcoma; (viii) prolongation of the period wherein the patient does not require to take antiretrovirals; (ix) increase of acceptance of pharmacological treatment; x. reduction of gastritis, nausea or vomiting, headache; (xi) reduction of cases with anemia or thrombocytopenia; and (xii) a change in the phase of the disease in the patient.

Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.